pan-90806
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02022540)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pan-90806
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03479372 | Phase 1/Phase 2 (Phase 2) | Apr 26, 2018 | PanOptica, Inc. |
| NCT02475109 | Phase 1 | Aug 1, 2015 | Gulf Coast Eye Institute, PanOptica, Inc. |
| NCT02022540 | Phase 1 | Feb 1, 2014 | PanOptica, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PanOptica, Inc. | For profit | 3 | 3 | 2 | 2014 |
| Gulf Coast Eye Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1